Skip to main content
Top
Published in: Journal of Gastroenterology 7/2009

01-07-2009 | Original Article—Liver, Pancreas, and Biliary Tract

Nonalcoholic fatty liver is a risk factor for postprandial hyperglycemia, but not for impaired fasting glucose

Authors: Tomoko Shiga, Yuriko Moriyoshi, Hikaru Nagahara, Keiko Shiratori

Published in: Journal of Gastroenterology | Issue 7/2009

Login to get access

Abstract

Purpose

The first aim of this study was to elucidate the relationship between impaired glucose tolerance (IGT) and nonalcoholic fatty liver. The second was to make a rule regarding to whom 75-g oral glucose tolerance tests (OGTTs) should be applied to identify subjects with IGT and diabetes mellitus (DM) in the annual check-up at the human dry dock.

Methods

A total of 716 subjects who visited the Department of General Medicine of the International Medical Center of Japan from May 2001 through January 2008 for an annual check-up at the human dry dock were analyzed. We evaluated risk factors related to nonalcoholic fatty liver using multivariate logistic regression analysis and compared the difference of body mass index (BMI) and glucose level at 75-g OGTT at two different time points in subjects whose fatty change had improved or worsened.

Results

Nonalcoholic fatty liver was strongly related to 2-h- and 1-h-post-challenge glucose level (P < 0.0001 and P = 0.018, respectively), but not fasting plasma glucose (FPG) (P = 0.706). The risk factors for IGT were nonalcoholic fatty liver (P < 0.05), low levels of high-density lipoprotein cholesterol (HDL-C) (P = 0.026) and age (P = 0.013). A clearly positive relationship was observed between the difference of BMI and 2-h-post-challenge glucose level among the subjects whose fatty change had improved or worsened (R = 0.6, P = 0.018).

Conclusions

Nonalcoholic fatty liver was clearly related to the 2-h- or 1-h-post-challenge glucose level, but not to FPG, in 75-g OGTT, and this IGT was corrected by body weight reduction in accordance with diminished nonalcoholic fatty liver. Thus, 75-g OGTT should be applied to subjects with nonalcoholic fatty liver to evaluate IGT.
Literature
1.
go back to reference Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullogh AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:413–1419.CrossRef Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullogh AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:413–1419.CrossRef
2.
go back to reference Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995;22:1714–9.PubMedCrossRef Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995;22:1714–9.PubMedCrossRef
3.
go back to reference Su C-C, Wang K, Hsia T-L, Chen C-S, Tung T-H. Association of nonalcoholic fatty liver disease with abnormal aminotransferase and postprandial hyperglycemia. J Clin Gastroenterol. 2006;40:551–4.PubMedCrossRef Su C-C, Wang K, Hsia T-L, Chen C-S, Tung T-H. Association of nonalcoholic fatty liver disease with abnormal aminotransferase and postprandial hyperglycemia. J Clin Gastroenterol. 2006;40:551–4.PubMedCrossRef
4.
6.
go back to reference Sargin M, Uygur-Bayramiçli O, Sargin H, Orbay E, Yayla A. Association of nonalcoholic fatty liver disease with insulin resistance. Is OGTT indicated in nonalcoholic fatty liver disease? J Clin Gastroenterol. 2003;37:399–402.PubMedCrossRef Sargin M, Uygur-Bayramiçli O, Sargin H, Orbay E, Yayla A. Association of nonalcoholic fatty liver disease with insulin resistance. Is OGTT indicated in nonalcoholic fatty liver disease? J Clin Gastroenterol. 2003;37:399–402.PubMedCrossRef
7.
go back to reference Frilis-Liby I, Aldenborg F, Jerlstad P, Rundström K, Björnsson E. High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease. Scand J Gastroenterol. 2004;9:864–9.CrossRef Frilis-Liby I, Aldenborg F, Jerlstad P, Rundström K, Björnsson E. High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease. Scand J Gastroenterol. 2004;9:864–9.CrossRef
8.
go back to reference National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979;28:1039–57. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979;28:1039–57.
9.
go back to reference Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20:1183–97. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20:1183–97.
10.
go back to reference Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation. Diabet Med. 1998;15:539–53. for the WHO Consultation.PubMedCrossRef Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation. Diabet Med. 1998;15:539–53. for the WHO Consultation.PubMedCrossRef
11.
go back to reference Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M, et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract. 2002;55:65–85.PubMedCrossRef Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M, et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract. 2002;55:65–85.PubMedCrossRef
12.
go back to reference Kawamori R. The role of the liver on post-prandial glycaemia-emphasis on hepatic glucose uptake. Int J Clin Prat Suppl. 2000;112:19–22. Kawamori R. The role of the liver on post-prandial glycaemia-emphasis on hepatic glucose uptake. Int J Clin Prat Suppl. 2000;112:19–22.
13.
go back to reference Mueller MJ, Boeker K, Selberg O. Metabolism of energy yielding substrates in patients with liver cirrhosis. Clin Invest. 1994;72:568–79. Mueller MJ, Boeker K, Selberg O. Metabolism of energy yielding substrates in patients with liver cirrhosis. Clin Invest. 1994;72:568–79.
14.
go back to reference Owen OE, Trapp VE, Rechard GA, et al. Nature and quantity of fuels consumed in patients with alcoholic cirrhosis. J Clin Invest. 1983;72:1821–32.PubMedCrossRef Owen OE, Trapp VE, Rechard GA, et al. Nature and quantity of fuels consumed in patients with alcoholic cirrhosis. J Clin Invest. 1983;72:1821–32.PubMedCrossRef
15.
go back to reference Verboeket-van de Venne WP, Weserterp KR, van Hoek B, Swart GR. Energy expenditure and substrate metabolism in patients with cirrhosis of the liver: effects of the pattern of food intake. Gut. 1995;36:110–6.PubMedCrossRef Verboeket-van de Venne WP, Weserterp KR, van Hoek B, Swart GR. Energy expenditure and substrate metabolism in patients with cirrhosis of the liver: effects of the pattern of food intake. Gut. 1995;36:110–6.PubMedCrossRef
16.
go back to reference Imano E, Kanda T, Nakatani Y, et al. Impaired splanchnic and peripheral glucose uptake in liver cirrhosis. J Hepatol. 1999;31:469–73.PubMedCrossRef Imano E, Kanda T, Nakatani Y, et al. Impaired splanchnic and peripheral glucose uptake in liver cirrhosis. J Hepatol. 1999;31:469–73.PubMedCrossRef
17.
go back to reference Kruszynska YT, Home PD, McIntyre N. Relationship between insulin sensitivity, insulin secretion and glucose tolerance in cirrhosis. Hepatology. 1991;14:103–11.PubMedCrossRef Kruszynska YT, Home PD, McIntyre N. Relationship between insulin sensitivity, insulin secretion and glucose tolerance in cirrhosis. Hepatology. 1991;14:103–11.PubMedCrossRef
18.
go back to reference Shmueli E, Walker M, Alberti G, Record CO. Normal splanchnic but impaired peripheral insulin-stimulated glucose uptake in cirrhosis. Hepatology. 1993;18:86–95.PubMedCrossRef Shmueli E, Walker M, Alberti G, Record CO. Normal splanchnic but impaired peripheral insulin-stimulated glucose uptake in cirrhosis. Hepatology. 1993;18:86–95.PubMedCrossRef
19.
go back to reference Leatherdale BA, Chase RA, Rogers J, Alberti KG, Davies P, Record CO. Forearm glucose uptake in cirrhosis and its relationship to glucose tolerance. Clin Sci. 1980;59:191–8.PubMed Leatherdale BA, Chase RA, Rogers J, Alberti KG, Davies P, Record CO. Forearm glucose uptake in cirrhosis and its relationship to glucose tolerance. Clin Sci. 1980;59:191–8.PubMed
20.
go back to reference Selberg O, Burchert W, vd Hoff J, Meyer GJ, Hundeshagen H, Radoch E, et al. Insulin resistance in liver cirrhosis. J Clin Invest. 1993;91:1897–902.PubMedCrossRef Selberg O, Burchert W, vd Hoff J, Meyer GJ, Hundeshagen H, Radoch E, et al. Insulin resistance in liver cirrhosis. J Clin Invest. 1993;91:1897–902.PubMedCrossRef
Metadata
Title
Nonalcoholic fatty liver is a risk factor for postprandial hyperglycemia, but not for impaired fasting glucose
Authors
Tomoko Shiga
Yuriko Moriyoshi
Hikaru Nagahara
Keiko Shiratori
Publication date
01-07-2009
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 7/2009
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-009-0059-1

Other articles of this Issue 7/2009

Journal of Gastroenterology 7/2009 Go to the issue

Original Article—Liver, Pancreas, and Biliary Tract

Long-term outcome of autoimmune pancreatitis

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.